AZN vs. BMRN: AstraZeneca vs. BioMarin Pharmaceutical Stock Comparison

Company Profile

AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AZN is classified in Pharmaceuticals while BMRN is classified in Biotechnology.

BioMarin Pharmaceutical (BMRN) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile AstraZeneca (AZN) reports 22.57%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile AstraZeneca (AZN) reports 17.68%, ranking against industry peers normally.

Both AstraZeneca (AZN) at 29.57% and BioMarin Pharmaceutical (BMRN) at 26.58% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both AstraZeneca (AZN) at 8.63% and BioMarin Pharmaceutical (BMRN) at 12.87% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both AstraZeneca (AZN) at 45.33% and BioMarin Pharmaceutical (BMRN) at -18.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both AstraZeneca (AZN) at 1.01 and BioMarin Pharmaceutical (BMRN) at 2.44 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both AstraZeneca (AZN) at 0.66 and BioMarin Pharmaceutical (BMRN) at 0.67 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

BioMarin Pharmaceutical (BMRN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: AstraZeneca (AZN) trades at 26.37 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while AstraZeneca (AZN) at 4.63 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both AstraZeneca (AZN) at 5.59 and BioMarin Pharmaceutical (BMRN) at 1.73 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics